A seasoned executive in the healthcare industry, Schiffman has over fifteen years of experience leading financial operations and strategies of international publicly traded companies such as Affymetrix and Applied Biosystems. Most recently, Schiffman held the role of Executive Vice President and CFO of Dendreon Corporation, where he had primary responsibility for capital raising, information technology, financial reporting and controls and investor relations. In April of 2010, Dendreon secured marketing authorization from the U.S. Food and Drug Administration (FDA) for Provenge(R), the world’s first cell–based autologous immunotherapy for prostate cancer, followed by European Commission authorization in September of 2013.
“We’re delighted to have Greg join StemCells as it transitions to Phase II, clinical proof of concept trials,” stated Martin McGlynn, President and Chief Executive Officer of StemCells, Inc. “Greg brings deep experience across all facets of finance and has a long history of helping emerging technology companies efficiently scale their operations, develop and launch new products, and expand into new markets. StemCells has an incredible team and first-in-class technology, and has cemented its position as one of the key technology innovators in the stem cell industry. I am very excited to bring Greg into the Company to build on its momentum and successes to date, and to help prepare the Company for commercial success.”
“StemCells has built its reputation on demanding excellence, world-class science and thoughtful product development,” commented Mr. Schiffman. “I believe the Company’s technology has the potential to be a game changer in the treatment of a vast range of disorders affecting the CNS, and I am thrilled to join StemCells at such an exciting time for the Company.”
Before entering the healthcare arena, Schiffman held key roles of responsibility with Hewlett Packard, where he acted as controller of its European P.C. manufacturing and distribution operations in Grenoble, France, and in addition as manufacturing manager and controller of its Netmetrix Division. Schiffman earned a bachelor’s degree in accounting from De Paul University and an MBA from the Kellogg Graduate School of Management at Northwestern University.
Schiffman is set to succeed Rodney Young, who has decided to pursue other opportunities. Commenting on the transition, McGlynn said, “Rodney’s time with StemCells was one of groundbreaking achievements, such as our successful completion of the first FDA-authorized study of human neural stem cells as well as initiation of the world’s first internationally approved study of these cells as a potential treatment for spinal cord injury. We wish Rodney well in his future endeavors and thank him for his service and dedication during his tenure as CFO at StemCells.”
To learn more, please visit www.stemcellsinc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
